Different effects of bortezomib on the expressions of various protein kinase C isoenzymes in T cells of patients with systemic lupus erythematosus and in Jurkat cells

Scandinavian Journal of Immunology

Volumn 75, Issue 2, 2012, Pages 243-248

  Griger, Z ^a   Toth B I ^b   Barath S ^a   Gyetvai, Á ^a   Kovacs I ^a   Tarr, T ^a   Biro T ^b   Zeher, M ^a   Sipka, S ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; PROTEIN KINASE C; PROTEIN KINASE C DELTA; PROTEIN KINASE C THETA; PROTEIN KINASE C ZETA; BORONIC ACID DERIVATIVE; ISOENZYME; PRKCD PROTEIN, HUMAN; PRKCE PROTEIN, HUMAN; PRKCQ PROTEIN, HUMAN; PROTEASOME INHIBITOR; PROTEIN KINASE C EPSILON; PYRAZINE DERIVATIVE;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; ANTIBODY SPECIFICITY; CASE CONTROL STUDY; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION; GENETICS; IMMUNOLOGY; JURKAT CELL LINE; MIDDLE AGED; PATHOLOGY; PRIMARY CELL CULTURE;

ADULT; APOPTOSIS; BORONIC ACIDS; CASE-CONTROL STUDIES; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION; HUMANS; ISOENZYMES; JURKAT CELLS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; ORGAN SPECIFICITY; PRIMARY CELL CULTURE; PROTEASOME INHIBITORS; PROTEIN KINASE C; PROTEIN KINASE C-DELTA; PROTEIN KINASE C-EPSILON; PYRAZINES; T-LYMPHOCYTES;

EID: 84855719269     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2011.02647.x     Document Type: Article

References (29)

1. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004;22:304-11.
2. Ben-Neriah Y. Regulatory functions of ubiquitination in the immune system. Nat Immunol 2002;3:20-6.
3. Cavo M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 2006;20:1341-52.
4. Dai Y, Rahman M, Grant S. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK and NF-κB dependent process. Oncogene 2003;22:7103-22.
5. Wang CY, Cusack JC, Liu R, Baldwin A Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999;5:412-7.
6. Durrant D, Liu J, Yang HS, Lee RM. The bortezomib-induced mitochondrial damage is mediated by accumulation of active protein kinase C-delta. Biochem Biophys Res Commun 2004;321:905-8.
7. Berges C, Haberstock H, Fuchs D et al. Proteasome inhibition suppresses essential immune functions of human CD4+T cells. Immunology 2008;124:234-46.
8. Sun K, Welniak LA, Panoskaltsis-Mortari A et al. Inhibition of acute graft-versus-host disease with retention of graft versus-tumor effects by proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 2004;101:8120-5.
9. Neubert K, Meister S, Moser K et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008;14:748-55.
10. van der Heijden JW, Oerlemans R, Lems WF, Scherper RJ, Dijkmans BA, Jansen G. The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients. Clin Exp Rheumatol 2009;27:92-8.
11. Yannaki E, Papadopoulou A, Athanasiou E et al. The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats. Arthritis Rheum 2010;62:3277-88.
12. Kyttaris VC, Krishnan S, Tsokos GS. Systems biology in systemic lupus erythematosus: integrating genes, biology and immune function. Autoimmunity 2006;39:705-9.
13. Perl A. Pathogenic mechanisms in systemic lupus erythematosus. Autoimmunity 2010;43:1-6.
14. Jury EC, Kabouridis PS, Abba A, Mageed RA, Isenberg DA. Increased ubiquitination and reduced expression of LCK in T lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 2003;48:1343-54.
15. Cordeiro AC, Isenberg DA. Novel therapies in lupus - focus on nephritis. Acta Rheumatol Port 2008;33:157-69.
16. Bertsias GK, Salmon JE, Boumpas DT. Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. Ann Rheum Dis 2010;99:1603-11.
17. Sestak AL, Fürnrohr BG, Harley JB, Merrill JT, Namjou B. The genetics of systemic lupus erythematosus and implications for targeted therapy. Ann Rheum Dis 2011;70 (Suppl. 1):i37-43.
18. Bíró T, Griger Z, Kiss E et al. Abnormal cell-specific expressions of certain protein kinase C isoenzymes in peripheral mononuclear cells of patients with systemic lupus erythematosus: effect of corticosteroid application. Scand J Immunol 2004;60:421-8.
19. Sun Z, Arendt CW, Ellmeier CW, Schaeffer EM, Sunshine MJ, Gandhi L. PKC theta is required for TCR-induced NF-kappa B activation in mature but not immature T lymphocytes. Nature 2000;404:402-7.
20. Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, Carvajal-Vergaga X, Mateos J, Vidriales B. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006;107:3575-83.
21. Reyland ME. Protein kinase C delta and apoptosis. Biochem Soc Trans 2007;35:1001-4.
22. Peng Y, Sigua CA, Karsonovich C, Murr MM. Protein kinase C-zeta (PKC-zeta) regulates Kupffer cell apoptosis during experimental sepsis. J Gastrointest Surg 2007;11:1712-21.
23. Yanaba K, Yoshazaki A, Muroi E et al. The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses. J Leukoc Biol 2010;88:117-22.
24. Veeranki S, Choubey D. Systemic lupus erythematosus and increased risk to develop B cell malignancies: role of the p200-family proteins. Immunol Lett 2010;133:1-5.
25. Chen JF, Jin J. Apoptosis in Jurkat cells induced by bortezomib combined with adriamycin. Zhonghua Zhong Liu Za Zhi 2009;31:890-3.
26. Basu B, Sarkar C, Chakroborty D et al. D1 and D2 dopamine receptor-mediated inhibition of activated normal T cell proliferation is lost in Jurkat T leukemic cells. J Biol Chem 2010;285:27026-32.
27. Jane EP, Premkumar DR, Pollack IF. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-(kappa)B signaling pathway. Mol Cancer Ther 2011;10:198-208.
28. Jakob CO, Zhu J, Armstrong DL et al. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci USA 2009;106:6256-61.
29. Loiarro M, Gallo G, Fanto N et al. Identification of critical residues of the MyD88 death domain involved in the recruitment of downstream kinases. J Biol Chem 2009;284:28093-103.